血清AFP、CA125、CA19-9联检在肝硬化和肝癌中的诊断价值

Clinical value of combining tumor maker alphafetoprotein(AFP),CA125 and CA19-9 in diagnose of liver cirrhosis and PHC

目的:探讨肿瘤标志物甲胎蛋白(AFP)、糖原抗原CA125与CA19-9在肝硬化和原发性肝癌(PHC)中的诊断价值。方法:对原发性肝癌(PHC)组50例、肝硬化组40例、慢性肝炎组45例和正常对照组30例,检测血清AFP、CA125和CA19-9水平。结果:PHC组血清AFP、CA125、CA19-9水平均明显高于肝炎组及正常对照组,差异有统计学意义(P<0.05)。PHC组血清AFP、CA125和CA19-9阳性率分别为70.0%、82.0%、90.0%,CA125、AFP联检阳性率为91.2%,AFP、CA125与CA19-9联检阳性率达97.3%。结论:血清AFP、CA125和CA19-9联合检测具有互补作用,特别是对AFP阴性、低浓度的PHC更具有诊断价值。

Objective： To investigate the clinical value of tumor marker alphafetoprotein （AFP）, CA125 and CA19-9 in the diagnose of liver cirrhosis and PHC. Methods： AFP, CA125 and CA19-9 in the serum were studied in 50 patients with PHC, 40 liver cirrhosis, 45 with hepatitis, and 30 healthy individuals. Results： The serum AFP, CA125 and CA19-9 in PHC were significantly higher than that in the hepatitis and healthy individuals （P 〈0. 05）. The positive detection rate of AFP, CA125 and CA19-9 in PHC was 70.0%, 82.0% and 90.0%, respectively and combined assay of CA125 and AFP was 91.2%, combined assay of AFP, CA125 and CA19-9 will increase the detecting rate up to 97.3%. Conclusion： The combining AFP, CA125 and CA19-9 examination has complementary function, which is superior to any single marker examination and can greatly increase the detecting rate of PHC and was valuable especially in those patients with negative or low serum level of AFP.